Aptcash Enterprises
Parel, Mumbai, Maharashtra
GST No. 27BDTPM3418D1ZF
TrustSEAL Verified
View Mobile No.
SEND EMAIL

Breast Cancer

Pioneers in the industry, we offer arimidex tablet (anastrozole) 1 mg tab and canassist-breast -an immunohistochemistry based test -cancer laboratories test from India.

Arimidex Tablet (Anastrozole) 1 Mg Tab

Arimidex Tablet (Anastrozole) 1 Mg Tab
  • Arimidex Tablet (Anastrozole) 1 Mg Tab
  • Arimidex Tablet (Anastrozole) 1 Mg Tab
  • Arimidex Tablet (Anastrozole) 1 Mg Tab
Get Best Quote
Approx. Price: Rs 100 / PieceGet Latest Price

Product Details:

BrandArmidex
Packaging Size28 Tab
Packaging TypeStrips
Active DrugAnastrozole
CompositionAnastrozole
ContentAnastrozole
Drug NameAnastrozole
Form Of MedicinesTablet
Medicine TypeHormonal Therapy
Number Of Tablets28 Tab
Strength1 Mg
Dose1 Mg

Anastrozole, sold under the brand name Arimidex used in addition to other treatments for breast cancer.Specifically it is used for hormone receptor-positive breast cancer. Also been used to prevent breast cancer in those at high risk.

Common side effects of anastrozole include hot flashes, altered mood, joint pain, and nausea.Severe side effects include an increased risk of heart disease and osteoporosis.Use during pregnancy may harm the baby.Anastrozole is in the aromatase-inhibiting family of medications.It works by blocking the production of estrogens in the body, and hence has antiestrogenic effects.

Medical uses - Breast cancer
Anastrozole is used in the treatment and prevention of breast cancer in women.The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was of localized breast cancer and women received either anastrozole, the selective estrogen receptor modulator tamoxifen, or both for five years, followed by five years of follow-up.After more than 5 years the group that received anastrozole had better results than the tamoxifen group.The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized estrogen receptor-positive breast cancer.
Early puberty

Anastrozole is used at a dosage of 0.5 to 1 mg/day in combination with the antiandrogen bicalutamide in the treatment of peripheral precocious puberty, for instance due to familial male-limited precocious puberty (testotoxicosis) and McCuneAlbright syndrome, in boys.
Contraindications
Contraindications of anastrozole include hypersensitivity to anastrozole or any other component of anastrozole formulations, pregnancy, and breastfeeding.Hypersensitivity reactions to anastrozole including anaphylaxis, angioedema, and urticaria have been observed.

Side effects

Common side effects of anastrozole (10% incidence) include hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, bone fractures, back pain, insomnia, headache, bone pain, peripheral edema, coughing, dyspnea, pharyngitis, and lymphedema.Serious but rare adverse effects (<0.1% incidence) include skin reactions such as lesions, ulcers, or blisters; allergic reactions with swelling of the face, lips, tongue, and/or throat that may cause difficulty swallowing or breathing; and abnormal liver function tests as well as hepatitis.
Pharmacodynamics
Anastrozole works by reversibly binding to the aromatase enzyme, and through competitive inhibition blocks the conversion of androgens to estrogens in peripheral (extragonadal) tissues.The medication has been found to achieve 96.7% to 97.3% inhibition of aromatase at a dosage of 1 mg/day and 98.1% inhibition of aromatase at a dosage of 10 mg/day in humans.As such, 1 mg/day is considered to be the minimal dosage required to achieve maximal suppression of aromatase with anastrozole.This decrease in aromatase activity results in an at least 85% decrease in estradiol levels in postmenopausal women.Levels of corticosteroids and other adrenal steroids are unaffected by anastrozole.
Pharmacodynamics of aromatase inhibitors
Pharmacokinetics
The bioavailability of anastrozole in humans is unknown, but it was found to be well-absorbed in animals.Absorption of anastrozole is linear over a dosage range of 1 to 20 mg/day in humans and does not change with repeated administration.Food does not significantly influence the extent of absorption of anastrozole.Peak levels of anastrozole occur a median 3 hours after administration, but with a wide range of 2 to 12 hours. Steady-state levels of anastrozole are achieved within 7 to 10 days of continuous administration, with 3.5-fold accumulation.However, maximal suppression of estradiol levels occurs within 3 or 4 days of therapy.
Request
Callback


Additional Information:

  • Packaging Details: 1mg 28 tab
Yes! I am Interested

CanAssist-Breast -An Immunohistochemistry Based Test -Cancer Laboratories Test

CanAssist-Breast -An Immunohistochemistry Based Test -Cancer Laboratories Test
  • CanAssist-Breast -An Immunohistochemistry Based Test -Cancer Laboratories Test
Get Best Quote
Approx. Price: Rs 150 / PersonGet Latest Price

Product Details:

Minimum Order Quantity1 Person
Treatment Typebreast cancer which is ER positive & PR positive but Her2 negative
Type Of Cancerbreast cancer which is ER positive & PR positive but Her2 negative
Usage/Applicationbreast cancer which is ER positive & PR positive but Her2 negative
TechnologyMethod Immunohistochemistry

CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and...
Date24 November 2018
EventESMO Asia 2018 Congress
SessionPoster display - Cocktail
TopicsBioethics, Legal, and Economic Issues
Personalised/Precision Medicine
Breast Cancer
Pathology/Molecular Biology
PresenterManjiri Bakre
CitationAnnals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426
AuthorsM. Bakre   Author Affiliations
Abstract Background

Current molecular risk stratification tests have helped clinicians to optimize chemotherapy for hormone receptor positive, HER2 negative early stage breast cancer patients leading to huge savings in treatment costs and improved quality of life. However, current tests are not impactful in the Asian subcontinent due to the extreme cost-sensitivity of the market. Aim of this study was to develop and validate a simple, cost-effective and accurate test based on insightful biomarkers involved in tumor recurrence using robust statistical methodology to stratify patients based on risk of recurrence.

Methods

A retrospective cohort of 300 patients, was used to develop ‘CanAssist-Breast’(CAB)- an immunohistochemistry based test comprising 5 biomarkers plus three clinical parameters (Tumor size, node status and grade) using machine learning based algorithm. Retrospective clinical validation on 850+ cases was performed and Kaplan Meier survival analysis, multivariate analysis was performed to assess robustness of the test.

Results

CanAssist-Breast classifies patients into ‘low or high’ risk of recurrence based on recurrence score on a scale of 1-100 with a cut off at 15.5. Clinical validation of CAB showed distant metastasis-free survival (DMFS) was significantly different between low- (DMFS: 95%) and high-risk (DMFS 80%) groups in the validation cohort treated with hormone therapy alone (n = 195) and in the entire validation cohort of 857 patients as well. In multivariate analysis, CAB risk score was the most significant independent predictor of distant recurrence with a hazard ratio of 4.25 (P = 0.009). Patients stratified as high-risk by CAB have 19% chemotherapy benefit. We also show that CAB can further identify discrete low- and high-risk sub-groups within IHC4 intermediate risk group and also in a node and age independent manner.

Conclusions

To our knowledge, CAB is the first machine learning based prognostic risk of recurrence prediction classifier using a combination of unique biomarkers and clinicopathological parameters. We believe that CAB enables accurate treatment planning in early stage HR+/HER2- breast cancer patients in low-resource settings.

Editorial acknowledgementClinical trial identificationLegal entity responsible for the study

OncoStem Diagnostics.

Request
Callback


Additional Information:

  • Delivery Time: Sample Daily by 3.30 pm; Report 15 days
  • Packaging Details: Test Name CAN ASSIST BREAST Report Availability Sample Daily by 3.30 pm; Report 15 days Code OS206 Test Components Specimen Submit Formalin fixed paraffin embedded tissue block. Ship at room temperature. Test is applicable only for Breast cancer which is ER positive & PR positive but Her2 negative. Duly filled Can Assist-Breast Test Requisition Form (Form 41) is mandatory. Stability Room NA Stability Refrigerated NA Stability Frozen NA Method Immunohistochemistry
Yes! I am Interested
X

Explore More Product



Reach Us
Aptcash Enterprises (Proprietor)
Aptcash Enterprises
Shop No. 7, B Wing, Nirmala Niwas, Aai Mai Merwanji Road
Parel, Mumbai - 400012, Maharashtra, India


Call Us
View Mobile No.


Send E-mailSend SMS